Immunogen (Immunogen) Margin of Safety % (DCF Dividends Based) : N/A (As of May. 26, 2024)

View and export this data going back to 1989. Start your Free Trial

What is Immunogen Margin of Safety % (DCF Dividends Based)?

Margin of Safety % (DCF Dividends Based) = (Intrinsic Value: DCF (Dividends Based) - Current Price) / Intrinsic Value: DCF (Dividends Based).

Note: Discounted Dividend model is only suitable for companies who have a consistant distribution history with more than 5 years. If the company's dividends does not remain steady over a long period, results may not be accurate due to the low consistency. The model is also only suitable for predictable companies (Business Predictability Rank higher than 1-Star). If the company's Predictability Rank is 1-Star or Not Rated, the data will not be stored into our database.

Immunogen's Predictability Rank is 1-Star. Thus, the DCF related results in the screener and portfolio will appear as zero and Margin of Safety % (DCF Dividends Based) is not calculated.

Competitive Comparison of Immunogen's Margin of Safety % (DCF Dividends Based)

For the Biotechnology subindustry, Immunogen's Margin of Safety % (DCF Dividends Based), along with its competitors' market caps and Margin of Safety % (DCF Dividends Based) data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Immunogen's Margin of Safety % (DCF Dividends Based) Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Immunogen's Margin of Safety % (DCF Dividends Based) distribution charts can be found below:

* The bar in red indicates where Immunogen's Margin of Safety % (DCF Dividends Based) falls into.

Immunogen Margin of Safety % (DCF Dividends Based) Related Terms

Thank you for viewing the detailed overview of Immunogen's Margin of Safety % (DCF Dividends Based) provided by GuruFocus.com. Please click on the following links to see related term pages.

Immunogen (Immunogen) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Immunogen Inc (NAS:IMGN) » Definitions » Margin of Safety % (DCF Dividends Based)

Comparable Companies

Traded in Other Exchanges

IMGN:Mexico IMU:Germany

Address

830 Winter Street, Waltham, MA, USA, 02451

Website

https://www.immunogen.com

Immunogen Inc is a clinical-stage biotechnology company from the United States. Its focus is antibody-drug conjugate, or ADC, technology, which uses an antibody that fixes on a target (its antigen) found on tumor cells to deliver a specific cancer-killing agent.

Executives

Theresa Wingrove	officer: VP of Regulatory Affairs	IMMUNOGEN, INC., 830 WINTER STREET, WALTHAM MA 02451
Renee Lentini	officer: V.P.-Fin., Prin. Acctg. Off.	830 WINTER STREET, WALTHAM MA 02451
Stacy Ann Coen	officer: Chief Business Officer	11 RUSH POND RD, LAKEVILLE MA 02347
Kristine Peterson	director	AMARIN CORPORATION, MYSTIC PACKER BLDG., 12 ROOSEVELT AVENUE, MYSTIC CT 06355
Lauren White	officer: SVP, CFO and PFO	C4 THERAPEUTICS, INC., 490 ARSENAL WAY, SUITE 200, WATERTOWN MA 02472
Mark J Enyedy	director, officer: Chief Executive Officer	C/O FATE THERAPEUTICS, INC., 3535 GENERAL ATOMICS COURT, SUITE 200, SAN DIEGO CA 92121
Isabel Kalofonos	officer: SVP & CHIEF COMMERCIAL OFFICER	C/O IMMUNOGEN, INC., 830 WINTER STREET, WALTHAM MA 02451
Michael Vasconcelles	officer: EVP R&D & MEDICAL AFFAIRS	C/O UNUM THERAPEUTICS, 200 CAMBRIDGEPARK DR., STE. 3100, CAMBRIDGE MA 02140
Daniel Char	officer: SVP & CHIEF LEGAL OFFICER	C/O EVELO BIOSCIENCES, INC., 620 MEMORIAL DRIVE, SUITE 200, CAMBRIDGE MA 02139
Kristen Harrington-smith	officer: SVP & Chief Commercial Officer	C/O IMMUNOGEN, INC., 830 WINTER STREET, WALTHAM MA 02451
Tracey L Mccain	director	C/O BLUEPRINTS MEDICINES CORPORATION, 38 SIDNEY STREET, SUITE 200, CAMBRIDGE MA 02139
Helen M. Thackray	director	C/O GLYCOMIMETICS, INC., 401 PROFESSIONAL DRIVE, SUITE 250, GAITHERSBURG MD 20879
David G Foster	officer: V.P.-Fin., Prin. Acctg. Off.	C/O IMMUNOGEN, INC., 830 WINTER STREET, WALTHAM MA 02451
Susan Altschuller	officer: SVP and CFO	45 TENNYSON ST., SOMERVILLE MA 02145
Craig Barrows	officer: Vice-President,General Counsel	C/O IMMUNOGEN, INC., 830 WINTER STREET, WALTHAM MA 02451